Table 1.
Patient characteristics at the time of right heart catheterization
| MACE (n = 30) | No MACE (n = 44) | P value | |
|---|---|---|---|
| Male n (%) | 23 (77) | 32 (73) | 0.70 |
| Donor age (years) | 46 ± 10 | 42 ± 13 | 0.22 |
| Age (years) | 52 ± 15 | 54 ± 10 | 0.44 |
| Time since transplantation (years) | 10 ± 7 | 5 ± 5 | <0.01 |
| NYHA functional class >1 n (%) | 13 (43) | 4 (9) | <0.001 |
| Body mass index (kg/m2) | 26 ± 4 | 25 ± 5 | 0.51 |
| CAV and previous rejections | |||
| Graft vasculopathy n (%) | 22 (73) | 10 (23) | <0.0001 |
| Previous percutaneous intervention | 8 (27) | 2 (5) | <0.01 |
| Number of EMBs showing 1R | 9 [6;11] | 7 [4;9] | 0.06 |
| Number of EMBs showing ≥2R | 1 [0;1] | 0 [0;1] | 0.14 |
| Biopsy‐score | 0.5 [0.3;0.6] | 0.5 [0.4–0.6] | 0.39 |
| Medication | |||
| Prednisolone n (%) | 15 (50) | 22 (50) | 1.00 |
| Cyclosporine n (%) | 12 (40) | 11 (25) | 0.17 |
| Tacrolimus n (%) | 18 (60) | 32 (73) | 0.25 |
| Mycophenolate n (%) | 21 (70) | 38 (86) | 0.09 |
| Everolimus n (%) | 9 (30) | 10 (23) | 0.48 |
| Statins n (%) | 27 (90) | 38 (86) | 0.64 |
| ACE/ATII inhibitor n (%) | 22 (73) | 29 (66) | 0.50 |
| Calcium blocker (%) | 10 (33) | 21 (48) | 0.22 |
| Aspirin (%) | 19 (63) | 16 (36) | <0.05 |
| Furosemid or bumetanide n (%) | 10 (33) | 7 (16) | 0.08 |
| Biochemistry | |||
| Creatinine (μmol/L) | 120 [80;152] | 100 [82;118] | 0.18 |
| Haemoglobin (mmol/L) | 8.2 ± 1.1 | 8.4 ± 1.0 | 0.47 |
| Troponin‐T (ng/L) | 18 [6;37] | 12 [6;19] | <0.05 |
| NT‐ProBNP (ng/L) | 501 [319;1746] | 364 [182;768] | <0.05 |
Data are presented as per cent or mean ± standard deviation or median and [IQR]. CAV, cardiac allograft vasculopathy; EMB, endomyocardial biopsy; MACE, major adverse cardiac events; NYHA, New York Heart Association.